Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research

BTIG Research assumed coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT - Free Report) in a report published on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $41.00 price target on the biotechnology company's stock.

A number of other research firms have also issued reports on ARCT. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright reaffirmed a "buy" rating and set a $63.00 target price on shares of Arcturus Therapeutics in a report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of "Buy" and an average target price of $61.60.

Arcturus Therapeutics Price Performance

Shares of ARCT traded down $0.25 during trading hours on Tuesday, reaching $17.17. 239,051 shares of the company's stock traded hands, compared to its average volume of 400,711. The firm has a market capitalization of $465.03 million, a price-to-earnings ratio of -7.69 and a beta of 2.63. Arcturus Therapeutics has a twelve month low of $14.30 and a twelve month high of $45.00. The business's fifty day simple moving average is $17.26 and its two-hundred day simple moving average is $19.54.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the previous year, the company earned ($0.61) earnings per share. On average, equities research analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company's stock worth $202,000 after acquiring an additional 846 shares during the period. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics during the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. boosted its position in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after acquiring an additional 2,038 shares during the period. Nordea Investment Management AB boosted its position in Arcturus Therapeutics by 3.7% during the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company's stock worth $1,097,000 after acquiring an additional 2,335 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company's stock worth $4,587,000 after acquiring an additional 3,224 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.